Pharma Equity is selling at 0.15 as of the 27th of November 2024; that is 6.25% down since the beginning of the trading day. The stock's open price was 0.16. Pharma Equity has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Pharma Equity Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Although Pharma Equity's alpha and beta are two of the key measurements used to evaluate Pharma Equity's performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharma Equity stock to make a market-neutral strategy. Peer analysis of Pharma Equity could also be used in its relative valuation, which is a method of valuing Pharma Equity by comparing valuation metrics with similar companies.